Literature DB >> 20388795

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.

Julie Vincent1, Grégoire Mignot, Fanny Chalmin, Sylvain Ladoire, Mélanie Bruchard, Angélique Chevriaux, François Martin, Lionel Apetoh, Cédric Rébé, François Ghiringhelli.   

Abstract

Myeloid-derived suppressor cells (MDSC) accumulate in the spleen and tumor bed during tumor growth. They contribute to the immune tolerance of cancer notably by inhibiting the function of CD8(+) T cells. Thus, their elimination may hamper tumor growth by enhancing antitumor T-cell functions. We have previously reported that some anticancer agents relied on T cell-dependent anticancer responses to achieve maximal efficacy. However, the effect of anticancer agents on MDSC has remained largely unexplored. In this study, we observed that gemcitabine and 5-fluorouracil (5FU) were selectively cytotoxic on MDSC. In vivo, the treatment of tumor-bearing mice with 5FU led to a major decrease in the number of MDSC in the spleens and tumor beds of animals whereas no significant effect on T cells, natural killer cells, dendritic cells, or B cells was noted. Interestingly, 5FU showed a stronger efficacy over gemcitabine to deplete MDSC and selectively induced MDSC apoptotic cell death in vitro and in vivo. The elimination of MDSC by 5FU increased IFN-gamma production by tumor-specific CD8(+) T cells infiltrating the tumor and promoted T cell-dependent antitumor responses in vivo. Altogether, these findings suggest that the antitumor effect of 5FU is mediated, at least in part, by its selective cytotoxic action on MDSC. (c) 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20388795     DOI: 10.1158/0008-5472.CAN-09-3690

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  458 in total

Review 1.  Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy.

Authors:  Enrico Proietti; Federica Moschella; Imerio Capone; Filippo Belardelli
Journal:  Mol Oncol       Date:  2011-12-03       Impact factor: 6.603

2.  Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin.

Authors:  Ruben Hernandez-Alcoceba; Pedro Berraondo
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

Review 3.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

4.  Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.

Authors:  Erik L Brincks; Tamara A Kucaba; Britnie R James; Katherine A Murphy; Kathryn L Schwertfeger; Veena Sangwan; Sulagna Banerjee; Ashok K Saluja; Thomas S Griffith
Journal:  FEBS J       Date:  2015-10-18       Impact factor: 5.542

5.  Mouse CD11b+Gr-1+ myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis.

Authors:  Huanfa Yi; Chunqing Guo; Xiaofei Yu; Daming Zuo; Xiang-Yang Wang
Journal:  J Immunol       Date:  2012-10-03       Impact factor: 5.422

Review 6.  Chemoimmunotherapy: reengineering tumor immunity.

Authors:  Gang Chen; Leisha A Emens
Journal:  Cancer Immunol Immunother       Date:  2013-02-07       Impact factor: 6.968

7.  Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study.

Authors:  C Mirjolet; C Charon-Barra; S Ladoire; F Arbez-Gindre; A Bertaut; F Ghiringhelli; A Leroux; D Peiffert; C Borg; J F Bosset; G Créhange
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

Review 8.  Chemotherapeutic targeting of cancer-induced immunosuppressive cells.

Authors:  Darya Alizadeh; Nicolas Larmonier
Journal:  Cancer Res       Date:  2014-04-28       Impact factor: 12.701

Review 9.  Tumor lysate-loaded biodegradable microparticles as cancer vaccines.

Authors:  Vijaya B Joshi; Sean M Geary; Brett P Gross; Amaraporn Wongrakpanich; Lyse A Norian; Aliasger K Salem
Journal:  Expert Rev Vaccines       Date:  2014-01       Impact factor: 5.217

10.  Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator.

Authors:  Prashant Trikha; Robert L Plews; Andrew Stiff; Shalini Gautam; Vincent Hsu; David Abood; Robert Wesolowski; Ian Landi; Xiaokui Mo; John Phay; Ching-Shih Chen; John Byrd; Michael Caligiuri; Susheela Tridandapani; William Carson
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.